Requires any amount paid on behalf of a health benefit plan enrollee to count toward the enrollee's cost-sharing
Summary
SB 187 would require health carriers and pharmacy benefit managers to count certain amounts paid by or on behalf of an enrollee toward that enrollee’s out-of-pocket maximum and other cost-sharing obligations under a health benefit plan. Specifically, the bill applies when the enrollee is paying for a medication for which no generic substitute is available. In those cases, the amount paid would have to be included in the enrollee’s overall cost-sharing calculation, whether the payment is made directly by the enrollee or on the enrollee’s behalf.
The bill also addresses how this rule would apply to health savings account-qualified high deductible health plans. If counting those payments immediately would conflict with federal HSA rules, the requirement would instead apply only after the enrollee has met the federal minimum deductible, except for preventive care services, which would be covered by the rule regardless of deductible status. The bill expressly preserves the ability of health carriers and health benefit plans to use step therapy under existing Missouri law.
Impact
SB 187 would add a new section to Missouri’s insurance code, chapter 376, creating a new cost-sharing rule for health benefit plans. It would affect health carriers, pharmacy benefit managers, and enrollees by changing how out-of-pocket spending is credited toward deductibles and annual maximums for certain brand-name medications without generic alternatives. The bill would also interact with federal tax rules governing HSA-qualified high deductible health plans, limiting its application where necessary to preserve HSA eligibility.
Sentiment
Based on the bill’s caption and the absence of recorded committee discussion or votes in the provided materials, the overall sentiment appears neutral and policy-oriented rather than overtly contentious. The bill is framed as a consumer cost-sharing measure intended to help enrollees receive credit for payments made toward expensive medications. No recorded testimony, amendments, or vote history is available here to indicate strong support or opposition.
Contention
The main potential point of contention is the bill’s effect on health plan costs and benefit design. Health carriers and pharmacy benefit managers may view the requirement as increasing plan liability or complicating administration, while consumers and patient advocates would likely favor it because it can accelerate progress toward deductibles and out-of-pocket maximums for high-cost drugs without generic substitutes. A secondary issue is the interaction with federal HSA rules, which the bill addresses by delaying application for certain high-deductible plans to avoid jeopardizing HSA eligibility. The bill also preserves step therapy, which may reduce opposition from insurers by leaving that utilization-management tool intact.